newsfilter
← Latest News
Business Wire·

4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome

New data demonstrating clinical activity in both IBS-C and IBS-D was presented at Digestive Disease Week 2021 Company to host webcast on Tuesday, May 25, 2021 at 12:00 p.m. EDT 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company lead